Ad-hoc press release: Revenue growth

Carl Zeiss Meditec increases revenue by around 7% in first nine months 2017/18 and adjusts revenue outlook

JENA/Germany, 2018-07-03.


Carl Zeiss Meditec (ISIN: DE0005313704) has achieved revenue of approximately EUR 926 million in the first nine months of fiscal year 2017/18, based on preliminary data. This corresponds to revenue growth of approximately 7% vs. the previous year’s value of EUR 864.7 million. After adjustment for currency effects1), growth amounted to around 12 %.

For the fiscal year 2017/18, Carl Zeiss Meditec now expects revenue of between EUR 1,250 to EUR 1,300 million (previously: EUR 1,230 to EUR 1,280 million).

At this point in time, further financial information is not yet available. The 9-months quarterly statement for fiscal year 2017/18 will be published on August 10, 2018.

1) Currency-adjusted sales growth is determined by weighting sales in the comparative period with current instead of actual historical exchange rates.



Contact for investors and press

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com





Carl Zeiss Meditec AG


Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,000 employees worldwide, the Group generated revenue of €1,189.9m in fiscal year 2016/17 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at:
www.zeiss.com/med